glucagon_receptor_antagonists-3_SDS_MedChemExpress

合集下载

蛇葡萄素对肝纤维化小鼠血清中ALT、AST含量及肝组织中Ⅰ、Ⅲ型胶原

蛇葡萄素对肝纤维化小鼠血清中ALT、AST含量及肝组织中Ⅰ、Ⅲ型胶原
关键词:蛇葡萄素;ALT;AST;胶原蛋白
1 材料 1.1 实验动物 昆明种小鼠48只,体质量(20±2)g,雌鼠和 雄鼠各一半的数量,均购自湖南莱克景达实验动物有限公 司,其许可证号为:SCXK(湘)2016-0002。 1.2 受试药物 蛇葡萄素由广西中医药大学中化教研室提
供,纯度97.5%。 1.3 主要试剂 秋水仙碱:Sigma分装,批号:201608;四 氯化 碳:国 药 集团化 学 试 剂 有限 公司,批号:2 0 13 0 514; AST、ALT试剂盒:由南京建成生物工程研究所所生产, 其 批号为:20170 614;其中动物组织总 R NA提 取试 剂
临床检验杂志(电子版) 2019年12月第8卷第4期 Clinical Laboratory Journal (Electronic Edition) December 2019, Vol.8 No.4 ·51·
mmoL/L,组间无差异(t=0.239, P>0.05)。参照组的Urea 含量指标测算值(4.86±1.20)mmoL/L与研究组大致相当 (4.90±1.19)mmoL/L,组间无差异(t=0.229, P>0.05)。 参照组的Cr含量指标测算值(83.2±13.4)μmoL/L与研究 组大致相当(82.1±12.7)μmoL/L,组间无差异(t=0.578, P>0.05)。参照组的Amy含量指标测算值(51.1±2.3)U/L 与研究组大致相当(52.5±1.1)U/L,组间无差异(t=6.324, P>0.05)。参照组的CHE含量指标测算值(6,616±1,825) U/L 与研 究 组 大 致 相当(6, 59 7±1, 7 57)U/L,组间无 差 异 (t=0.073, P>0.05)。参照组的CK含量指标测算值(118.1± 176.4)U/L与研究组大致相当(121.4±177.0)U/L,组间无 差异(t=0.128, P>0.05)。

高中生物 蛋白质的聚丙烯酰胺凝胶电泳

高中生物 蛋白质的聚丙烯酰胺凝胶电泳

实验四蛋白质的聚丙烯酰胺凝胶电泳最广泛使用的不连续缓冲系统最早是由Ornstein(1964) 和Davis(1964) 设计的, 样品和浓缩胶中含Tris-HCl(pH 6.8), 上下槽缓冲液含Tris-甘氨酸(pH 8.3), 分离胶中含Tris-HCl(pH 8.8)。

系统中所有组分都含有0.1% 的SDS(Laemmli, 1970)。

样品和浓缩胶中的氯离子形成移动界面的先导边界而甘氨酸分子则组成尾随边界,在移动界面的两边界之间是一电导较低而电位滴度较陡的区域, 它推动样品中的蛋白质前移并在分离胶前沿积聚。

此处pH值较高,有利于甘氨酸的离子化,所形成的甘氨酸离子穿过堆集的蛋白质并紧随氯离子之后,沿分离胶泳动。

从移动界面中解脱后,SDS-蛋白质复合物成一电位和pH值均匀的区带泳动穿过分离胶,并被筛分而依各自的大小得到分离。

SDS与蛋白质结合后引起蛋白质构象的改变。

SDS-蛋白质复合物的流体力学和光学性质表明,它们在水溶液中的形状,近似于雪茄烟形状的长椭园棒,不同蛋白质的SDS复合物的短轴长度都一样(约为18Å,即1.8nm),而长轴则随蛋白质分子量成正比地变化。

这样的SDS-蛋白质复合物,在凝胶电泳中的迁移率,不再受蛋白质原有电荷和形状的影响,而只是椭园棒的长度也就是蛋白质分子量的函数。

由于SDS和巯基乙醇的作用,蛋白质完全变性和解聚,解离成亚基或单个肽链,因此测定的结果只是亚基或单条肽链的分子量。

SDS聚丙烯酰胺凝胶的有效分离笵围取决于用于灌胶的聚丙烯酰胺的浓度和交联度。

在没有交联剂的情况下聚合的丙烯酰胺形成毫无价值的粘稠溶液,而经双丙烯酰胺交联后凝胶的刚性和抗张强度都有所增加,并形成SDS蛋白质复合物必须通过的小孔。

这些小孔的孔径随“双丙烯酰胺~丙烯酰胺”比率的增加而变小,比率接近1:20 时孔径达到最小值。

SDS聚丙烯酰胺凝胶大多按“双丙烯酰胺~丙烯酰胺”为1:29 配制,试验表明它能分离大小相差只有3% 的蛋白质。

果胶酶活性检测试剂盒说明书 微量法

果胶酶活性检测试剂盒说明书 微量法

果胶酶活性检测试剂盒说明书微量法注意:正式测定之前选择2-3个预期差异大的样本做预测定。

货号:BC2635规格:100T/48S产品内容:提取液:液体100mL×1瓶,4℃保存。

试剂一:液体25mL×1瓶,4℃保存。

若溶液中有不溶解物质,可以50℃水浴溶解。

试剂二:液体20mL×1瓶,4℃避光保存。

标准品:粉剂×1支,10mg半乳糖醛酸。

临用前加入0.943mL蒸馏水,配成50μmol/mL的标准液产品说明:果胶酶(pectinase)是分解果胶的酶类,包括原果胶酶,果胶酯酶,多聚半乳糖醛酸酶和果胶裂解酶四大类,广泛存在于高等植物果实和微生物中,是水果加工中最重要的酶。

果胶酶水解果胶生成半乳糖醛酸,半乳糖醛酸与DNS试剂反应生成在540nm有特征吸收峰的棕红色物质,测定540nm处吸光值变化可计算得果胶酶活性。

试验中所需的仪器和试剂:可见分光光度计/酶标仪、台式离心机、水浴锅、微量玻璃比色皿/96孔板、可调式移液枪、研钵/匀浆器、冰和蒸馏水。

操作步骤:一、粗酶液提取:组织:按照组织质量(g):提取液体积(mL)为1:5~10的比例(建议称取约0.1g组织,加入1mL提取液)进行冰浴匀浆,然后10000g,4℃,离心10min,取上清置于冰上待测。

菌类:按照细胞数量(104个):提取液体积(mL)为500~1000:1的比例(建议500万细胞加入1mL 提取液),冰浴超声波破碎细胞(功率300w,超声3秒,间隔7秒,总时间3min);然后10000g,4℃,离心10min,取上清置于冰上待测。

液体:直接检测。

二、测定步骤:1、分光光度计/酶标仪预热30min以上,调节波长至540nm,蒸馏水调零。

2、将50μmol/mL标准液用蒸馏水稀释为10、8、6、4、2、1μmol/mL的标准溶液备用。

3、取40μL样本沸水浴10min备用。

4、操作表:(在1.5mL离心管中)对照管测定管标准管空白管试剂一(µL)20020020020050℃水浴温育5min标准溶液(µL)--40-样本(µL)-40--蒸馏水(µL)---40煮沸样本(µL)40---混匀,50℃水浴反应30min,马上沸水浴5min,冷却后8000g,常温离心10min,取上清。

谷氨酸(Glu)含量检测试剂盒说明书(WST 法)__ 微量法UPLC-MS-6012

谷氨酸(Glu)含量检测试剂盒说明书(WST 法)__ 微量法UPLC-MS-6012

44谷氨酸(Glu )含量检测试剂盒说明书(WST 法)货号:UPLC-MS-6012规格:100T/48S产品组成:使用前请认真核对试剂体积与瓶内体积是否一致,有疑问请及时联系工作人员。

试剂名称规格保存条件试剂一液体85mL×1瓶2-8℃试剂二液体 1.5mL×1支2-8℃试剂三粉剂×2瓶-20℃保存试剂四粉剂×2支-20℃保存试剂五液体4mL×1瓶2-8℃保存标准液液体0.5mL×1支2-8℃保存溶液的配制:1、试剂三:临用前取1瓶加入6mL 试剂一,用不完的试剂-20℃分装保存4周,避免反复冻融;2、试剂四:临用前取1支加入0.5mL 试剂二,用不完的试剂-20℃分装保存2周,避免反复冻融;3、标准液:10μmol/mL 谷氨酸标准品。

微量法产品说明:Glu 广泛存在于动物、植物、微生物和培养细胞中,不仅是组成蛋白质的20种氨基酸之一,而且通过转氨基作用参与多种氨基酸合成,是生物体内主要氨基来源之一。

此外,Glu 还是味精的主要有效成分,常用做食品添加剂以及香料生产。

谷氨酸脱氢酶(GDH )催化谷氨酸和NAD 生成α-酮戊二酸、NADH 和NH +,在1-mPMS 作用下,WST-1可与NADH 反应,产生水溶性formazan ,计算谷氨酸含量。

Glutamate+NAD +++NADHNADH+WST-1formazan (450nm )注意:实验之前建议选择2-3个预期差异大的样本做预实验。

如果样本吸光值不在测量范围内建议稀释或者增加样本量进行检测。

需自备的仪器和用品:分光光度计/酶标仪、台式离心机、可调式移液器、微量玻璃比色皿/96孔板、研钵/匀浆器、超声破碎仪、冰、蒸馏水。

操作步骤:一、样本处理(可适当调整待测样本量,具体比例可以参考文献)细菌、细胞:收集细菌或细胞到离心管内,离心后弃上清;按照每500万细菌或细胞加入1mL 试剂一,超声波破碎细菌或细胞(功率200w ,超声3s ,间隔10s ,重复30次),10000g ,常温离心10min ,取上清待测。

人磷脂酰肌醇蛋白聚糖3酶联免疫分析试剂盒使用方法

人磷脂酰肌醇蛋白聚糖3酶联免疫分析试剂盒使用方法

人磷脂酰肌醇蛋白聚糖3酶联免疫分析试剂盒使用方法检测范围:96T0.3μg/L -12μg/L使用目的:本试剂盒用于测定人血清、血浆及相关液体样本中磷脂酰肌醇蛋白聚糖3含量。

实验原理本试剂盒应用双抗体夹心法测定标本中人磷脂酰肌醇蛋白聚糖3水平。

用纯化的人磷脂酰肌醇蛋白聚糖3抗体包被微孔板,制成固相抗体,往包被单抗的微孔中依次加入磷脂酰肌醇蛋白聚糖3,再与HRP标记的磷脂酰肌醇蛋白聚糖3抗体结合,形成抗体-抗原-酶标抗体复合物,经过彻底洗涤后加底物TMB显色。

TMB在HRP酶的催化下转化成蓝色,并在酸的作用下转化成最终的黄色。

颜色的深浅和样品中的磷脂酰肌醇蛋白聚糖3呈正相关。

用酶标仪在450nm波长下测定吸光度(OD值),通过标准曲线计算样品中人磷脂酰肌醇蛋白聚糖3浓度。

试剂盒组成1.标本采集后尽早进行提取,提取按相关文献进行,提取后应尽快进行实验。

若不能马上进行试验,可将标本放于-20℃保存,但应避免反复冻融2.不能检测含NaN3的样品,因NaN3抑制辣根过氧化物酶的(HRP)活性。

操作步骤1.标准品的稀释:本试剂盒提供原倍标准品一支,用户可按照下列图表在小试管中进行稀2.加样:分别设空白孔(空白对照孔不加样品及酶标试剂,其余各步操作相同)、标准孔、待测样品孔。

在酶标包被板上标准品准确加样50μl,待测样品孔中先加样品稀释液40μl,然后再加待测样品10μl(样品最终稀释度为5倍)。

加样将样品加于酶标板孔底部,尽量不触及孔壁,轻轻晃动混匀。

3.温育:用封板膜封板后置37℃温育30分钟。

4.配液:将30倍浓缩洗涤液用蒸馏水30倍稀释后备用5.洗涤:小心揭掉封板膜,弃去液体,甩干,每孔加满洗涤液,静置30秒后弃去,如此重复5次,拍干。

6.加酶:每孔加入酶标试剂50μl,空白孔除外。

7.温育:操作同3。

8.洗涤:操作同5。

9.显色:每孔先加入显色剂A50μl,再加入显色剂B50μl,轻轻震荡混匀,37℃避光显色15分钟.10.终止:每孔加终止液50μl,终止反应(此时蓝色立转黄色)。

多糖

多糖

葡萄糖脑苷脂
半乳糖脑苷脂
神经节苷脂 ganglioside;GA ): 1.结构:
从神经节细胞分离的一种鞘糖脂。其脂质部分是神 经酰胺,除通过糖苷键相连的糖基(多为单糖)外, 还携有一个或多个唾液酸残基,属酸性鞘糖脂的 一种,另一种是硫酸鞘糖脂(硫苷脂)。主要存在 于神经组织、脾脏与胸腺中。 2.应用前景:GM能够介导神经生长因子NGF促进 脑神经细胞再生,表现出良好的生物效应。NGF 和GM目前无论在试验中,还是临床实践里都显 示出对神经系统促进恢复效果,已成为研究的热 点。如这两种药物协同作用能得到充分应用,必 将能为中枢神经疾病患者带来更大希望。
硫酸角质素(keratan sulfate) 1.结构:糖胺聚糖的一种,由半乳糖和N-乙 酰氨基葡糖形成的重复二糖单位组成的多 糖,并在两种糖基的C-6位羟基处都可能 有硫酸根取代。 与蛋白质形成结合体存在于哺乳类的角膜、 椎间板、软骨和动脉中,也就是以蛋白多 糖(proteoglgcan)形式存在的一种粘多糖。 在多数情况下和硫酸软骨素共存,也有时 两者只有一个蛋白质部分。
的水分,为目前所公认的最佳保湿成分,
透明质酸的主要功能有如 下四点: 1.美容(除皱,丰唇,填充 脸部,隆鼻,填充凹痕) 无副作用 2、改善关节功能 3、天然的保湿润滑剂 4、防止动脉硬化、脉搏紊 乱和脑萎缩等病症的发 生。
玻尿酸
硫酸皮肤素 (dermatan sulfate): 1.结构:糖胺聚糖的一种,由N-乙酰氨基半乳 糖-β-1,4-L-艾杜糖醛酸-α(或D-葡萄糖醛酸-β)1,3的二糖重复单位构成的多糖。在N-乙酰氨 基半乳糖的C-4位等处常有硫酸根取代。 2.功能:硫酸皮肤素(DS)是糖胺聚糖,为血 管壁蛋白多糖的主要成份,作用: (1)、DS与心脑血管疾病(抗凝作用) (2)、DS与炎症 (3)、DS与肿瘤 (4)· DS与感染 (5)DS与损伤修复

谷氨酰胺转氨酶交联的原位明胶止血剂体外凝血实验的研究

谷氨酰胺转氨酶交联的原位明胶止血剂体外凝血实验的研究
重 复 3次 。结 果 : G 组凝 血 时间 明显少 于 1 1 1 药品 HI M . .
凝 血 酶组 及 空 白组 ( < . 1 ; IM 组 凝 血 P 00 ) HG
实验 用 明胶 溶 液 和 T 酶 由北 京 化 工 大 G
块 重量 明显少 于空 白组 ( < . 1 , 与凝 血 学提供 。凝血酶冻干粉 (0 I 由北京第 一 P 0 0 )而 50U ) 酶 相 比无 统计 学 意 义 ( >0 0 ) P .5 。与 空 白组 生物化学药业有 限公司提供 。氯化钙注射液 及凝 血 酶 组 相 比 , IM 组 凝 血 块 颜 色 较 深 , ( . /0H ) HG 0 5g 1 d 由上海信谊金朱药业有限公司
第3 2卷第 l 期 21 0 2年 3月
e c 0 气e
明 胶 科 学 与 技 术 T eS i c n eh o g f e t h c n eadTcn l yo G l n e o a i
Vo . 2 No 1 13 . Ma . 01 . r2 2
研究报告 S
疗组 、 阳性 对 照 组 和 阴性 对 照组 , 疗 组 加 入 原位明胶 , 治 探讨其体外凝血时间。 HIM、 G 阳性对 照组 加 入 凝 血 酶 和 阴性 对 照 组 加入 生 理盐 水 。记 录各 组凝 血 时间 、 血 块重 1 资 料与 方 法 凝 量及 颜 色 、 积 , 进 行 组织 病 理 学 检查 。共 1 1 药物 的 制备 体 并 .
多, 创伤已成为继心脑血管疾病 和恶性肿瘤之 者以 172的容积 比配制而成。 ::
外最大的死亡原因。严重创伤的高死 亡率和 凝血酶组的凝 血酶溶 液与 H G IM相 比含

联 系人 e —ma : ie@ 13 Cr i t nr 6 . O lx n

葡萄糖脱氢酶法的英文

葡萄糖脱氢酶法的英文

葡萄糖脱氢酶法的英文Glucose Dehydrogenase Method.The glucose dehydrogenase method is a spectrophotometric assay for determining the concentration of glucose in a sample. It is based on the enzymatic reaction catalyzed by glucose dehydrogenase (GDH), which oxidizes glucose to gluconic acid and reduces NAD+ to NADH. The amount of NADH produced is stoichiometrically equivalent to the amount of glucose in the sample, and can be measured by its absorbance at 340 nm.The reaction is carried out in a cuvette containing a buffer, GDH, NAD+, and the sample. The change in absorbance at 340 nm is monitored over time, and the rate of change is used to calculate the concentration of glucose in the sample.The glucose dehydrogenase method is a simple, rapid, and accurate method for determining the concentration ofglucose in a variety of samples, including blood, urine, and food products. It is commonly used in clinical chemistry laboratories and in food analysis.Principle of the Method.The glucose dehydrogenase method is based on the following enzymatic reaction:Glucose + NAD+ + H2O → Gluconic acid + NADH + H+。

lc3-β检测主要原理

lc3-β检测主要原理

lc3-β检测主要原理
LC3-β (Microtubule-associated protein 1 light chain 3 beta) 检测是一种用于检测细胞自噬活动的方法。

LC3 是一个与细胞
自噬相关的蛋白,包括 LC3-I 和 LC3-II 两种形式。

LC3-I 是未修饰
的形式,在细胞质中广泛存在,LC3-II 是修饰后的形式,主要定位在
自噬液泡膜上。

LC3-β 检测的主要原理是通过免疫荧光染色或免疫印迹技术检
测 LC3 的表达和定位。

免疫荧光染色可以直接观察到细胞内的 LC3
分布情况,而免疫印迹则可以通过检测 LC3 的蛋白表达水平来判断细
胞中自噬的活性。

在免疫荧光染色中,首先需要使用特异性的抗体标记 LC3,通常
使用抗 LC3 的抗体结合荧光染料标记抗体。

然后将该混合物加入待检
测的细胞样品中进行孵育,使抗体与特定的抗原结合。

最后用荧光显
微镜观察细胞内的荧光强度和分布,可以判断细胞中 LC3 的定位情况。

在免疫印迹中,首先需要提取细胞蛋白,并使用聚丙烯酰胺凝胶
电泳(SDS-PAGE)将蛋白分离。

然后将蛋白转移到膜上,并使用特异
性的抗体与膜上的 LC3 结合。

最后通过荧光或化学发光技术检测抗体
与 LC3 的结合情况,从而确定 LC3 的表达水平。

通过以上原理和技术,可以判断细胞中 LC3 的表达及其定位情况,从而间接反映细胞自噬的活性。

Glucagon-receptor-antagonists-1-SDS-MedChemExpress

Glucagon-receptor-antagonists-1-SDS-MedChemExpress

Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Oct.-03-2018Print Date:Oct.-03-20181. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :glucagon receptor antagonists-1Catalog No. :HY-10036CAS No. :503559-84-01.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:3-Pyridinemethanol, 4-[4-fluoro-2-(phenylmethoxy)phenyl]-.alpha.-methyl-2,6-bis(1-methylethyl)-5-(1-propen-1-yl)-Formula:C29H34FNO2Molecular Weight:447.58CAS No. :503559-84-04. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2018 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

绞股蓝皂苷对痴呆小鼠认知能力的作用及其机制

绞股蓝皂苷对痴呆小鼠认知能力的作用及其机制

绞股蓝皂苷对痴呆小鼠认知能力的作用及其机制刘梅讯;孙天敏【期刊名称】《中国医药导报》【年(卷),期】2017(014)013【摘要】目的探讨绞股蓝皂苷(GPs)对痴呆小鼠认知能力的作用及其机制.方法联合使用三氯化铝、D-半乳糖和亚硝酸钠复制阿尔茨海默病(AD)小鼠模型;按照随机数字表法分为:AD模型组、GPs 50 mg/kg组、GPs 150 mg/kg组、GPs 250mg/kg组、安理申组及正常组;3个GPs组给予不同剂量的GPs,连续给药3个月,观察各组抗氧化指标和形态学染色的差异.结果GPs 250 mg/kg组与AD模型组、GPs 150 mg/kg组比较,潜伏期、第一次穿越原平台位置时间明显缩短(P< 0.05或P<0.01),而在原平台象限的活动时间明显变长(P< 0.05或P< 0.01),且接近正常组(P>0.05).与AD模型组比较,GPs 150 mg/kg组、GPs 250 mg/kg组超氧化物歧化酶(SOD)、谷胱甘肽过氧化酶(GSH-Px)活性依次升高(P<0.05),而丙二醛(MDA)含量依次降低(P<0.05);且GPs 250 mg/kg组上述三个指标接近正常组(P>0.05).HE染色:AD模型组海马CA2区锥体细胞数量少、排列不整齐,结构模糊,而GPs250 mg/kg组神经元数量多,排列较均匀、整齐,结构较清晰.结论 GPs通过抗氧化等作用保护海马神经元,从而改善痴呆小鼠的认知能力.%Objective To discuss function and its mechanism of Gypenosides (GPs) on improving cognitive competence of dementia mice.Methods Alzheimer's disease (AD) mice model was copied by combining alchlor,D-galactose and sodium nitrite.According to the random number table method,these mice were divided into AD model group,GPs 50 mg/kg group,GPs 150 mg/kggroup,GPs 250 mg/kg group,Aricept group and normal group randomly.Three GPs groups were injected with different doses of GPs for three consecutive months to observe the differences in anti-oxidative index and morphological staining pattern of the three groups.Results The incubation period and the time when the original platform position was passed through for the first time were shortened significantly (P < 0.05 or P < 0.01),GPs 250 mg/kg group comparied with AD model group and GPs150 mg/kg group,the activity time in the original platform quadrant extended obviously (P < 0.05 or P < 0.01),and it closes to the normal group (P > 0.05).Comparied with AD model group,the SOD,GSH-Px activities of GPs 150 mg/kg group,GPs 250 mg/kg group rose respectively (P < 0.05),and MDA concentration decreased (P < 0.05),but the above four indexes of GPs 250 mg/kg group were approximate to the normal group (P > 0.05).HE staining:the quantity of pyramidal cells in hippocampal CA2 sector decreased and arranged irregularly with an obscure structure.But there was a large amount of neuron in GPs 250mg/kg group,which arranged evenly and orderly with a clear structure.Conclusion GPs protects hippocampal neuron by its anti-oxidability,further improving the cognitive competence of dementia mice.【总页数】4页(P17-20)【作者】刘梅讯;孙天敏【作者单位】湖北医药学院附属太和医院医学影像中心,湖北十堰442000;湖北医药学院图书馆,湖北十堰442000【正文语种】中文【中图分类】R749.16;R-332【相关文献】1.绞股蓝总皂苷对血管性痴呆大鼠神经元的保护作用 [J], 齐刚;张莉;等2.绞股蓝总皂苷对血管性痴呆大鼠海马一氧化氮合酶阳性神经元及核酸的保护作用研究 [J], 齐刚;杨程;张莉;吴光亮;熊杰;李积胜3.人参皂苷Rb3联合β-细辛醚对血管性痴呆模型小鼠的改善作用及其机制研究[J], 邓敏贞;钟晓琴;高志杰;孙一凡;黄丽平4.绞股蓝皂苷调控长链非编码RNA TUG1/miR-26a干扰线粒体凋亡对ApoE-/-AS小鼠肝脏脂质沉积的影响及机制研究 [J], 宋囡;曹慧敏;陈丝;王莹;王杰;王群;贾连群;杨关林5.绞股蓝总皂苷对血管性痴呆大鼠海马一氧化氮合酶及核酸的保护作用 [J], 齐刚;张莉;吴光亮;熊杰;李积胜因版权原因,仅展示原文概要,查看原文内容请购买。

桑椹来源的寡核苷酸显著改善小鼠骨质疏松症

桑椹来源的寡核苷酸显著改善小鼠骨质疏松症

桑椹来源的寡核苷酸显著改善小鼠骨质疏松症穆雪萌;杜芯仪;王彦超;金云峰;张嘉【期刊名称】《动物营养学报》【年(卷),期】2024(36)1【摘要】本试验旨在探究桑椹来源的寡核苷酸ASON-OP对小鼠骨质疏松症的改善作用。

将30只雌性小鼠随机分为5组,分别为假手术组、模型对照组、阳性药物组、ASON-OP组和ASON-NC组(ASON-NC为无义序列,作为阴性对照),每组6只。

除假手术组小鼠以外,其他4组小鼠均进行双侧卵巢切除(OVX),构建骨质疏松症小鼠模型。

建模成功后,继续饲养1周,而后进行给药处理。

假手术组和模型对照组每天灌胃300μL生理盐水;阳性对照组皮下注射特立帕肽,剂量为80μg/(kg BW·d),1周给药5次;ASON-NC组每天灌胃ASON-NC溶液,剂量为2 mg/(kg BW·d);ASON-OP组每天灌胃ASON-OP溶液,剂量为2 mg/(kg BW·d)。

连续给药4周后,检测小鼠骨组织微结构、骨转化指标等。

结果显示:与模型对照组和ASON-NC组相比,连续4周灌胃寡核苷酸ASON-OP显著增加了OVX小鼠的骨密度(P<0.05);显著提高了OVX小鼠血清成骨因子骨钙素(OCN)含量(P<0.05),显著降低了血清破骨因子Ⅰ型胶原C末端肽(CTX-1)含量(P<0.05);显著提高了OVX 小鼠股骨中促进成骨相关基因Runt相关转录因子2(Runx2)、肝/骨/肾型碱性磷酸酶(Alpl)、骨钙素(Bglap)的mRNA相对表达量(P<0.05)。

综上所述,桑椹来源的寡核苷酸ASON-OP具有显著的抗骨质疏松症作用。

【总页数】8页(P602-609)【作者】穆雪萌;杜芯仪;王彦超;金云峰;张嘉【作者单位】中国医学科学院北京协和医院骨科;中国医学科学院北京协和医学院基础学院;上海弗艾柏生物科技有限公司;北京优准生物科技有限公司【正文语种】中文【中图分类】R274【相关文献】1.电话护理教育显著改善绝经后妇女骨质疏松症用药依从性和降低骨折发生率2.小鼠肾小管上皮细胞来源外泌体改善脓毒症肾脏损伤炎症反应的研究3.骨髓间充质干细胞来源小细胞外囊泡对骨质疏松症的改善作用4.天然植物来源的3,4-二羟基苯甲醛改善雄性小鼠生殖损伤的作用5.南极磷虾肽对去卵巢骨质疏松症小鼠肠钙吸收的改善作用研究因版权原因,仅展示原文概要,查看原文内容请购买。

血糖检测试剂盒原料toos底物还可以检测哪些项目

血糖检测试剂盒原料toos底物还可以检测哪些项目

TOOS可以用哪些检测项目
TOOS全称为N-乙基-N-(2-羟基-3-磺丙基)-3-甲基苯胺钠盐,是一种有着广泛应用的体外诊断试剂,在新型Trinder's试剂里最为常用。

TOOS在许多临床生化检测项目中都有应用。

TOOS通过Trinder反应,被广泛用于诊断检测和生化试验,Trinder反应又称“偶联终点比色法”,原理是被测物质通过酶作用产生的过氧化氢在4—氨基安替比林、过氧化物酶的存在下,可生成红色醌亚胺化合物。

血糖检测项目:TOOS在血糖代谢项目中用于制备葡萄糖检测试剂、糖化白蛋白检测试
剂等。

根据相关报道描述,利用葡萄糖氧化酶催化葡萄糖氧化生成过氧化氢,铂铋纳米模拟过氧化物酶催化MBTH和TOOS偶合显色,显色产物溶液颜色为紫色,随着葡萄糖浓度的增大,溶液颜色加深,显色体系的最大吸收波长为590nm,由590nm处吸光度可得出葡萄糖的含量。

肝功能常规检查项目:腺苷脱氨酶活性是反映肝损伤的敏感指标,是肝功能常规检查项目之一,TOOS和牛血清白蛋白、乙二胺四乙酸二钠等组成腺苷脱氨酶检测试剂,具有显色效果好,反应迅速、稳定、测定精密度高等优点。

另外TOOS还用于甘油三酯等血脂检测项目和胆固醇检测等项目的诊断试剂中,在临床诊断中具有重要价值。

甘油三酯试剂盒使用说明书

甘油三酯试剂盒使用说明书
计算:
A样品
甘油三酯浓度=X校准浓度(mmol/L或mg/dl)
A校准
参考值:
正常值范围v1.71mmol/L(150mg/dl)
临界值1.71mmol/L~2.26mmol/L(150mg/dl~200mg/dl)
高甘油三酯症〉2.26mmol/L(200mg/dl)
各医院应根据本地区实际情况建立自己的参考值。
自己从试剂说明书上打的, 主要是为了了解酶比色法测定甘
油三酯的原理。
甘油三酯试剂盒使用说明书
Triglycerides Kit (TG)酶色法通用型(冻干粉)用途:
本试机用于测定人血清中甘油三酯的浓度。 测定原理:
甘油三酯+3H2。LPS'甘油+脂肪酸
甘油+ATPGK—;甘油-3-磷酸+ADP
甘油-3-磷酸+02GPO>磷酸二羟丙酮+H2O2
线性上限:'
甘油三酯浓度可达11.29mmol/L(100mg/dl)
主要性能指标:
1.试剂空白吸光度:在500nm(480~520nm)处,A<0.1。
2.准确性:相对偏差不超过土10%。
3.瓶间差:变异系数(CV%)<4%
4.批间差:随机抽取三批试剂盒的批间差w6%。
5.线性误差:在1.13mmol/L~11.29mmol/L范围内不超过土10%。
4.本产品仅用于体外诊断,内含叠氨钠,应避免直接接触皮肤和眼睛,切勿吞咽。
5.本产品应在2~8C条件下贮存。
6.若试剂在全自动生化分析仪上使用,可参照本公司提供的相应型号仪器的参数,并在本
公司技术人员指导下使用。
禁忌症:暂未发现
波长:500nm(480~520nm)
  1. 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
  2. 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
  3. 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。

Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Jun.-20-2017Print Date:Jun.-20-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :glucagon receptor antagonists-3Catalog No. :HY-50159CAS No. :202917-17-71.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:3–Pyridinemethanol,4–(4–fluoro–2–hydroxyphenyl)–.alpha.–methyl–2,6–bis(1–methylethyl)–5–propyl–, (.alpha.R,4R)–rel– (9CI)Formula:C22H30FNO2Molecular Weight:359.48CAS No. :202917-17-74. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

相关文档
最新文档